Status:
COMPLETED
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Lead Sponsor:
Johns Hopkins University
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipi...
Detailed Description
Kidney transplantation is widely recognized as the optimal therapy for the management of end-stage renal disease. Presently, the deceased donor kidney waiting list has expanded disproportionately with...
Eligibility Criteria
Inclusion
- Adult (18 years or older)
- End-stage renal disease
- Identified to have positive lymphocytotoxic crossmatch or flow cytometric crossmatch with live donor
Exclusion
- Deceased donor recipients
- Pregnancy
- Active infection
- History of cancer within the past two years (with the exception of non-melanomatous skin cancer)
- History of heparin induced thrombocytopenia
- Medical contraindications to transplant procedure
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00275509
Start Date
January 1 2007
End Date
June 1 2010
Last Update
January 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Johns Hopkins University, School of Medicine
Baltimore, Maryland, United States, 21205